Back

Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

26 May 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Cardiovascular Disease in Special Populations Cardio-Oncology HFA Premium Access Heart Failure 2019

About the speaker

Photo
Miss Nathalie Bouwer

Albert Schweitzer Hospital, Dordrecht (Netherlands (The))

13 More presentations in this session

Presentation thumbnail
Doctor M. Tettamanti (Buenos Aires, AR)
Abstract Slides
Presentation thumbnail
Doctor S. Hadzibegovic (Berlin, DE)
Abstract
Presentation thumbnail
Doctor A. Lena (Berlin, DE)
Abstract
Presentation thumbnail
Ms L. Lueck (Berlin, DE)
Abstract
Presentation thumbnail
Doctor A. Ntalianis (Athens, GR)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Cardiovascular Disease in Special Populations

The Event

Event poster

Heart Failure 2019

26 May 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular toxicity surveillance in metastatic breast cancer patients receiving long-term HER2-targeted therapy: a retrospective multicentre study
21 June 2025
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025
thumbnail
Congress Presentation
The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.
28 August 2023
thumbnail
Webinar
A practical guide to cardiotoxicity risk stratification with ESC Guidelines on Cardio-Oncology
11 February 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources